AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Day One Biopharmaceutical... (DAWN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.21

0.43 (3.65%)

At close: Feb 20, 2025, 3:59 PM

12.23

0.12%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	11.59
Market Cap	1.23B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.97
PE Ratio (ttm)	-12.59
Forward PE	n/a
Analyst	Buy

Ask	12.36
Volume	679,243
Avg. Volume (20D)	974,157
Open	11.76
Previous Close	11.78
Day's Range	11.69 - 12.24
52-Week Range	11.13 - 18.07
Beta	undefined

About DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral s...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 27, 2021

Employees 174

Stock Exchange NASDAQ

Ticker Symbol DAWN

Website https://dayonebio.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 211.09% from the latest price.

Buy 85.71%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Day One Biopharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+0.84%

Day One Biopharmaceuticals shares are trading high... Unlock content with Pro Subscription

News

1 week ago · zacks.com

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre...

1 week ago · zacks.com

New Strong Buy Stocks for February 13th

SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.

1 month ago · seekingalpha.com

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has signi...

1 month ago · zacks.com

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.

1 month ago · seekingalpha.com

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with ...